Embecta names Devdatt Kurdikar as board chairman

Embecta Corp. (NASDAQ: EMBC) announced that its board of directors elected Devdatt "Dev" Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately.

The changes follow the retirement of LTG (Ret.) David F. Melcher, who served as Non-Executive Chairman of the Board. The company cited Melcher's commitments outside of his service to the company as the reason for his departure.

Kurdikar, 57, joined BD (Becton, Dickinson and Company) in 2021 to lead the diabetes care business and became president and chief executive officer of Embecta when it spun off from BD in 2022. He also serves on the boards of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed and LMG Holdings.

"I am honored that my fellow Board members have placed their faith in me to continue to drive this progress while leading our transformation into a more broad-based medical supplies company," Kurdikar said.

Dr. Pomeroy, 70, has served on Embecta's board since the company's inception in 2022. She will continue to chair the Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee. Since 2013, she has served as president of the Albert and Mary Lasker Foundation. She also serves as a director of Haemonetics Corporation and on several other boards.

"I wish to thank the Board for their trust and support as we work together to carry out embecta's mission to empower people with diabetes today while paving the way for a life unlimited for all," Dr. Pomeroy said.

Embecta describes itself as advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company. The company employs approximately 2,000 people globally.

You May Also Be Interested In